Sarah Gheuens Sells $151K of Agios Pharmaceuticals Inc (AGIO) — SEC Form 4, Jul 02, 2026

Open-Market Net Sale · SEC Form 4

−$150,503

10b5-1 Plan (Partial)

Equity position changed by +5.2%

Reporting Owner

Sarah Gheuens

Officer

TXN 2026-07-01 · FILED 2026-07-02

Equity Position 88.7K sh 84,284 → 88,652

Equity Change +5.2% shares held after vs before

Filing Lag 1 business day within 2-day SEC deadline

Form 4 · Statement of Changes in Beneficial Ownership

Agios Pharmaceuticals Inc

AGIO CIK 0001439222

Reporting Owner

Name	Relationship
Sarah Gheuens CIK 0001881190	Officer

Sarah Gheuens at Agios Pharmaceuticals Inc Full insider history

Bought (12 mo) —

Sold (12 mo) $1,851,121

More from this insider at Agios Pharmaceuticals Inc

Non-Derivative Securities Transactions

Title	Date	Type	Shares	Price	Net Total	Post-Txn	Ownership
Common stock	2026-07-01	M - Exercise 10b5-1	8,375 A	$0.00	—	88,652	Direct
Common stockF1	2026-07-01	S - Sale 10b5-1	4,007 D	$37.56	-$150,503	84,645	Direct

Derivative Securities Transactions

Title	Strike	Date	Type	Shares	Price	Expiration	Underlying	Ownership
Restricted stock unitsF2 F3 F3		2026-07-01	M - Exercise	8,375 D	$0.00		8,375 Common stock	Direct

Footnotes (3)

F1: Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's restricted stock units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated July 1, 2023. Show more
F2: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Show more
F3: The restricted stock units were granted on July 1, 2023. Beginning on July 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments. Show more

Institutional Holders

Largest by reported value

5%+ Holders · 13D/G 7 filers

Latest Schedule 13D/G per filer; stakes the filer reported closed are left out.

Other insiders at Agios Pharmaceuticals Inc

GET /v1/forms/4/0001439222-26-000110 API docs